Track topics on Twitter Track topics that are important to you
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune diseases, neurodegenerative diseases and diabetes mellitus.
202, 279 Midpark Way SE
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Admin...
Based on a growing body of data demonstrating apabetalone's beneficial attributes as a latency-reversing agent for advancing HIV-1 eradication, Resverlogix is seeking a partner for future developm...
Aside from the recent funding and Phase 3 trial news, Resverlogix has many milestones for investors to look forward to this year. The post Resverlogix CEO Discusses Phase 3 BETonMACE Clinical Trial ap...
Resverlogix Corp. licensed Medison Pharma Ltd. exclusive rights to market and distribute apabetalone (RVX208) in Israel and the Palestine Authority.
Resverlogix Corp. (epigenetic therapeutics) secured a $30mm 12-month senior secured term loan with Third Eye Capital. The loan will bear interest at 10% per annum and the lender will receive up to 3....
CALGARY, Alberta, April 12, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has received a 30-day extension to no later than May 14, 2018 ...
CALGARY, May 10, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that, following the previously announced review, the Continued Listing Committ...
CALGARY, Alberta, May 07, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced US$30 million senior secu...
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class ...
Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...
NEC Corporation of America (NEC) is a leading technology integrator providing solutions that improve the way people work and communicate. NEC delivers integrated Solutions for Soc...
We have published hundreds of Resverlogix Corporation news stories on BioPortfolio along with dozens of Resverlogix Corporation Clinical Trials and PubMed Articles about Resverlogix Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Resverlogix Corporation Companies in our database. You can also find out about relevant Resverlogix Corporation Drugs and Medications on this site too.
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...